Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

Psoriasis: dysregulation of innate immunity

Author(s): Bos JD, de Rie MA, Teunissen MB, Piskin G

Abstract

The current understanding of the function of natural killer (NK) T cells in innate immunity and their potential to control acquired specific immunity, as well as the remarkable efficacy of antitumour necrosis factor-alpha biological treatments in psoriasis, forces us to refine the current T-cell hypothesis of psoriasis pathogenesis, and to give credit to the role of innate immunity. Psoriasis might be envisioned to be a genetically determined triggered state of otherwise dormant innate immunity. This aggravated state of innate immunity is represented by the activity of NK T cells, dendritic cells, neutrophils and keratinocytes, leading to the recruitment and activation of preferentially type 1 T cells, possibly in an antigen-independent way. Keratinocytes in psoriasis then are sensitive to the effects of T-cell activation and cytokine production, interferon (IFN)-gamma, by responding with psoriasiform hyperplasia. The chronic inflammation of psoriatic lesions suggests that this might be due to a deficiency in downregulation processes (e.g. a defect in the regulatory T-cell repertoire) and/or the persistence of an unknown trigger resulting in an exaggerated innate immune response.

Similar Articles

Pathogenesis and therapy of psoriasis

Author(s): Lowes MA, Bowcock AM, Krueger JG

Interleukine-1 and interleukine- 6 in psoriasis

Author(s): Prens EP, Benne K, van DJ, Bakkus M, Brakel K, et al.

The IL-23/ Th 17 Axis in the Immunopathogenesis of Psoriasis

Author(s): Cesare DC, Meglio PD, Nestle FO

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

Author(s): Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, et al.

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Author(s): Chaudhari U, Romano P, Mulcahy L, Dooley L, B aker D, et al.

Demonstration of novel innate immune cells in psoriasis

Author(s): Mak R, Hundhausen C, Botti E, Laggner U, Grys K, et al.

Histopathologic spectrum of psoriasis

Author(s): Murphy M, Philip K, Grant- Kels JM